New Delhi: The global pharmaceutical scene is changing, and it’s causing ripples for India, the once-dominant “pharmacy of the world.” For years, India has excelled in producing generic medicines and vaccines, but now it faces rising competition from China.
Reports highlight a significant shift as China rapidly advances in drug research and development. Their number of early-stage drug programs and clinical trials is increasing, outpacing many global players. “This shift shows a major move from low-cost manufacturing to innovative drug development,” noted Vinod Kalani, an advisor at the Confederation of Pharmaceutical Industry of India.
India remains a key player in the pharmaceutical market. In 2024–25, its exports hit USD 30.47 billion, growing 9.4% from the previous year. This is largely due to its solid manufacturing base and expanding global reach. Currently, India provides nearly 20% of the world’s generic drug exports.
Commerce Secretary Rajesh Agrawal mentioned that India’s domestic market is valued at about USD 60 billion and could double to USD 130 billion by 2030. This growth indicates the industry’s potential. However, analysts warn that China’s push into innovative drug discovery could pose a threat, especially as they invest in advanced therapies.
“India’s challenge is not in manufacturing but in stepping up to original drug research,” Kalani added. China’s extensive investments have allowed many global pharmaceutical giants to partner with their firms, boosting innovation there.
India is also trying to cut its reliance on Chinese pharmaceutical raw materials, especially Active Pharmaceutical Ingredients (APIs). Despite being a leading exporter of finished medicines, India still leans heavily on China for key components.
To combat this, the Indian government has rolled out the Production-Linked Incentive (PLI) Scheme. With a budget of Rs 6,940 crore, it aims to promote domestic manufacturing of critical components in the pharmaceutical industry. As of December 2025, 48 projects have been approved under this scheme, with substantial investments already made.
Maintaining an edge will require India to innovate further. Experts underscore the importance of increasing investment in research and development. Shifts in global geopolitics could open doors for Indian firms as Western countries seek to diversify their dependence on Chinese manufacturing.
In addition, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) was launched to provide affordable, quality generic medicines through special stores called Jan Aushadhi Kendras. Medicines available through this initiative can be 50% to 80% cheaper than branded options, making a real difference in patients’ healthcare costs.
Looking ahead, India’s pharmaceutical future depends not just on cost-effective production but also on bolstering research and collaborations that keep pace with global innovations. As Kalani explains, “The future of pharma hinges on discovering the medicines of tomorrow.”
For further insights into this changing landscape, you can follow reputable sources like the [World Health Organization](https://www.who.int) or explore detailed reports from [McKinsey & Company](https://www.mckinsey.com) about global pharmaceutical trends.
Source link
PHARMACEUTICAL MANUFACTURING INDIA, PHARMACEUTICAL MANUFACTURING CHINA, PHARMACEUTICAL MANUFACTURING, INDIA, CHINESE PHARMACEUTICALS, RISE OF CHINESE PHARMACEUTICAL INDUSTRY POSES A CHALLENGE FOR INDIA
